Your browser doesn't support javascript.
loading
Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang, Yuehong; Singh, Ratnakar; Wang, Liguang; Nilsson, Monique; Goonatilake, Ruchitha; Tong, Pan; Li, Lerong; Giri, Uma; Villalobos, Pamela; Mino, Barbara; Rodriguez-Canales, Jaime; Wistuba, Ignacio; Wang, Jing; Heymach, John V; Johnson, Faye M.
Afiliação
  • Wang Y; Department of Respiratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
  • Singh R; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Wang L; Institute of Oncology, Provincial Hospital Affiliated to Shandong University, Shandong University, Jinan, China.
  • Nilsson M; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Goonatilake R; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Tong P; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Li L; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Giri U; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Villalobos P; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Mino B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Rodriguez-Canales J; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Wistuba I; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Wang J; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Heymach JV; The University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA.
  • Johnson FM; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Oncotarget ; 7(30): 47998-48010, 2016 Jul 26.
Article em En | MEDLINE | ID: mdl-27384992
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pteridinas / Proteínas Proto-Oncogênicas / Proteínas Serina-Treonina Quinases / Carcinoma Pulmonar de Células não Pequenas / Proteínas de Ciclo Celular / Inibidores de Proteínas Quinases / Receptores ErbB / Cloridrato de Erlotinib / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pteridinas / Proteínas Proto-Oncogênicas / Proteínas Serina-Treonina Quinases / Carcinoma Pulmonar de Células não Pequenas / Proteínas de Ciclo Celular / Inibidores de Proteínas Quinases / Receptores ErbB / Cloridrato de Erlotinib / Neoplasias Pulmonares Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Oncotarget Ano de publicação: 2016 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos